anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
1,223,763. Chymotrypsin B. L&#39;OPOCHIMIE. 29 Oct., 1968 [3 Nov., 1967], No. 51160/68. Heading C3H. In a process for obtaining chymotrypsin B by a fractionated precipitation of the proteins contained in a pulpy pancreas mixture followed by dissolution of the final cake in cold water, activation with trypsin and chromatographic purification, a first amount of ammonium sulphate is added to reach a degree of saturation of about 0À2, the mixture obtained is then filtered free of proteins of very high molecular weight and non-proteinaceous impurities, a second amount of ammonium sulphate is added to the filtrate to reach a degree of saturation comprised between 0À4 and 0À5 and the resulting mixture is filtered, giving a final cake the weight of which is approximately equal to 20% of that of the raw mixture of precipitable proteins contained in the aqueous extract before adding thereto said second amount of ammonium sulphate, said cake is redissolved in water, trypsin is added to the resulting solution in a quantity substantially equal to 1/40 of the weight of proteins contained in said solution, as determined from spectrophotometric readings, and the chymotrypsin B contained in the trypsinactivated solution is separated from other enzymes and proteins by a single chromatography. The cake may be dialysed to remove ammonium sulphate before the activation step.
[GB1223763A]
PURPOSE:To activate differentiation and induction of macrophage, etc., by integrating a DNA corresponding to a specific amino acid sequence. CONSTITUTION:A cell obtained by cultivating human acute monocytic leukemic cell strain THP-1 is subjected to RNA extracting treatment to give mRNA (A) to code cell human differentiating and inducing substance. Then the component A is subjected to plasmid recombination treatment to give a gene (B) of cell differentiating and inducing substance. Then the component B is connected to a gene sequence in a desired 5&#39; range and bonded to a vector such as bacterium to give a recombinant gene (C). Then the component D is transduced into Escherichia coli to give a transformant. Then the transformant is cultivated in a medium to give a cell differentiating and inducing substance having an amino acid sequence shown by the formula.
Medicaments for topical application for the treatment of psoriasis consist of an inert pharmaceutical carrier contg. an effective amount of prostaglandin E1 (PGE1) or prostaglandin E2, opt. together with a phosphodiesterase inhibitor (pref. theophylline, papaverin e or 5-chloro-6-ethylamino-1,3-dihydro-2H-imidazo 4,5-b pyrazin-2-one)- . Pref. medicaments contain 0.05-5 wt % PGE1 or PGE2 and 0.05-5 wt % phosphodiesterase inhibitor. The medicaments are pref. administered topically or by injection into the affected areas. Topical formulations include aerosol sprays, powder sprays, isotonic aqs. solns. lotions, creams, ointments, and solid salve sticks. The specification includes results of in vitro tests showing that PGE1 or PGE2 or their combinations with theophylline increase the concentration of cyclic AMP in normal human skin, psoriatic plaques, and &#39;normal adjoining&#39; skin tissue. Present knowledge of the relationship between skin cyclic AMP concentrations and psoriasis indicates that PGE1 or PGE2, opt. together with a phosphodiesterase inhibitor, constitutes an effective treatment of psoriasis.
Described embodiments include a system, method, and computer program product. A described system includes a receiver circuit that receives a first medical image. The first medical image includes a selected target region of interest of an individual patient&#39;s body part, and a landmark subsurface feature of the individual patient&#39;s body part having a first spatial relationship with the selected target region. The receiver circuit receives a second medical image that includes a candidate region of interest of the individual patient&#39;s body part, and a landmark feature of the individual&#39;s patient body part having a second spatial relationship with the candidate region. A feature matching circuit determines a correspondence between the candidate landmark subsurface feature and the associated landmark subsurface feature. A reporting circuit generates informational data indicating the second medical image includes at least a portion of the selected target region of interest. A communication circuit outputs the informational data.
The invention relates to radiopharmaceuticals which preferentially accumulate in myocardial tissue. The invention particularly relates to a radiopharmaceutical composition which contains as effective radioactive compound a Tc(III)-DMPE complex with a chloride ion and a hydroxyl group as coligands. A process for preparing this composition entails technetate(VII) being reacted with the reducing ligand DMPE in one step to give the desired complex by, to prepare the inactive precursor (instant kit), together with the DMPE . HCl from aqueous alcoholic solution, additives of mannitol and either a dicarboxylic acid, an aminopolycarboxylic acid or a polyaminocarboxylic acid being lyophilised, and a 1/1 mixture of pertechnetate generator eluate and propylene glycol being added to this lyophilised mixture, and the mixture being heated until conversion to (Tc(DMPE)2Cl(OH))&lt;+&gt; is complete. After neutralisation with NaHCO3 solution, the solution is ready for injection. This composition permits images of the myocardium which can be satisfactorily evaluated to be obtained up to 4 hours after the injection.
This cross-sectional study conducted with 40 women with GDM diagnosed with two-step 100g oral glucose tolerance test and 40 healthy women, aged 21-41 years, between weeks of 14-28 of pregnancy, who attended the Department of Obstetrics and Gynecology of Gulhane Training and Research Hospital. Participants with polycystic ovary syndrome, chronic diseases, pre-GDM, or multiple pregnancies were excluded. Sociodemographic information was recorded via questionnaire and anthropometrics of women were measured.

Blood samples were taken after an overnight fasting. Dietary information was obtained by mean intakes of a 3-day food records (2 weekdays and 1 weekend day) and analyzed via nutrition analysis software. According to the data obtained from software analysis, animal protein (g/day) to potassium (g/day) ratio (AP/K), potential renal acid load (PRAL; mEq/day) score and net endogenous acid production (NEAP; mEq/day) were calculated from established algorithms to estimate dietary acid load. All nutrients were age and energy- adjusted before being introduced into the equation and tertiles of the scores were used for statistical analysis. ANOVA, ANCOVA and Logistic regression test were used. The study plan was approved by the Hospital\&#39;s Ethics Committee.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide electrolyzed reductive water for treating athlete&#39;s foot capable of performing the extermination of fungi and curing acceleration of wound simultaneously by directly applying the electrolyzed reductive water (1) produced by the electrolysis and having active hydrogen on the athlete&#39;s foot or ringworm caused by the infection with the fungi such as Trichophyton, on the surface of foot, or the like.  &lt;P&gt;SOLUTION: This electrolyzed reductive water for treating the athlete&#39;s foot kills the Trichophyton by suffocating with the action of eliminating oxygen caused by the reducing reaction of active hydrogen contained in the electrolyzed reductive water (1), prevents oxidation by its action of inhibiting active oxygen, improves blood flow and prompts the activity of cells to promote the cure. Since water molecule is small, it penetrates into a hard affected part such as a keratinous layer by a capillary phenomenon-promoting action to improve its effect. Since the component is water, there is no pain by irritation or adverse effect. By an aseptic effect to prevent the oxidation of organic substances, a deodorizing effect is obtained. Thus, a new and safe method for treating the athlete&#39;s foot having an excellent effect is provided.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To obtain cryoprecipitate contg. fibrinogen at a low ratio by providing a line for supplying a physiological salt soln. to be added to the thick red blood cell liquid which is separated from a membrane type plasma separator and is returned to a donor and an auxiliary filtrate plasma line for supplying lean cryoprecipitate. CONSTITUTION:This separating device consists of a line 21 for adding and transporting an anticoagulant to blood, the membrane type plasma separator 2 for separating this blood to a blood cell component and a plasma component, a cooler 12 for controlling the separated plasma to -10 to 6 deg.C, a filter 8 loaded with a membrane of 0.1 to 10mu pore size for separating the plasma from the cooler 12 to rich cryoprecipitate and lean cryoprecipitate, and a storage vessel 13 kept at &lt;=6 deg.C to house the rich cryoprecipitate passed through the filter. the blood return line 19 to return the thick red blood cell liquid which is the blood cell component separated from the membrane type plasma separator 2 to the donor is provided to this device. The replenishing liquid such as physiological salt soln. is mixed with the thick red blood cell liquid by an auxiliary liquid supply pump 7 and the supply of the lean cryoprecipitate to the return line 17 is changed, by which the line is connected to a thick red blood cell liquid transporting line 18.
A method of reducing respiratory alkalosis (high blood pH) and enhancing productivity (rate of weight gain) in poultry during periods of chronic or acute heat stress (high heat and humidity) involving the steps of supplementing the birds&#39; diet (feedstuffs and/or water) with acids (hydrogen ion donor) and bicarbonate donors (NaHCO 3 ) or supplementing the birds&#39; drinking water with additional potassium ion (e.g. KCl or K 2  CO 3 ) and/or ammonium chloride with or without NaHCO 3  and ascorbic acid. The addition of an acid donor as a poultry feed or water additive and the use of additional potassium in the drinking water significantly reduces the alkalosis induced mortality rate and enhances the rate of weight gain (up to 30 percent). By including NaHCO 3  in the feed ration, the rate of gain is further enhanced (an additional 9 percent). The further intention addition of a sodium free, chloride ion donor also promotes increased rate of gain. The use of a H 2  antagonist (cimetidine) to reduce stomach acid production is also beneficial to increase growth rate and mortality by reducing blood pH.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means and a method for efficiently controlling an interprotein interaction.  &lt;P&gt;SOLUTION: The autoagglutination type regulatory molecule is obtained by fusing a molecule for regulating the function of a target protein with an autoagglutination molecule and has regulatory ability of the function of the target protein and autoagglutination ability. The complex is obtained by autoagglutinating the autoagglutination type regulatory molecule. The polynucleotide is obtained by fusing a molecule for regulating the function of a target protein with an autoagglutination molecule and encodes an autoagglutination type regulatory polypeptide having regulatory ability of the function of the target protein and autoagglutination ability. The expression vector contains the polynucleotide. The method for controlling an interprotein interaction comprises bringing the complex obtained by agglutination of the autoagglutination type regulatory molecule into contact with the target protein.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
DNAs encoding glutamate and avermectin-sensitive chloride channels have been cloned and characterized. The individual alpha and beta subunits are capable of forming homomeric and heteromeric channels selectively opened with either avermectin or glutamate. The cDNA&#39;s have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified. Receptor modulators are useful as insecticides and anthelminthic agents.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a toothpaste package wherein the adhesion of a toothpaste to the internal layer surface of a packaging container is extremely less, by which a user can easily and beautifully use up the toothpaste, for which various kinds of packaging containers can be used, and which has an excellent usability and beautiful appearance not seen in a conventional one.  &lt;P&gt;SOLUTION: This toothpaste package comprises the tooth paste and a toothpaste packaging container. In this case for the tooth paste, 10 g of the tooth paste is placed in a test tube which contains a water soluble macromolecular compound and an interfacial active agent, and has a diameter of 16.5 mm, and then, the liquid component is freed to the surface layer by performing a centrifugal separation under conditions of the case at 1,900 G for 10 minutes. The toothpaste packaging container is filled with a packages the toothpaste. In this case, the packaging container has the internal layer surface which satisfies A/B≤0.95 or A/B≥1.1 for a ratio between a surface tension A of the liquid component being freed from the toothpaste surface layer, and a critical surface tension B of the packaging container internal layer surface.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
PURPOSE:To prepare a solution of sodium hexametaphosphate in a short time, by adding a solution of sodium bicarbonate, potassium bicarbonate, potassium carbonate or sodium carbonate to powdery sodium hexametaphosphate. CONSTITUTION:The powdery sodium hexametaphosphate used as the raw material is prepared by weighing a definite amount of the powder having a purity of &gt;= about 75%, and sterilizing with ultraviolet irradiation. The sodium bicarbonate, potassium bicarbonate, sodium carbonate or potassium carbonate has a purity of &gt;= about 99%, and is used singly or in combination. The concentration of the solution is 1-20w/v%, and the solution is added to the powdery sodium hexametaphosphate. The dissolution completes within about 10-20min with slight agitation. A solution of sodium bicarbonate, etc. is added to the product to adjust the pH. The preparation process is carried out under an oseptic condition.
New aminooxylipids of general formula (I), wherein n= 5-30 and X is a polymethylene linker of the general formula (II) where n= 2 -10, or X is a polyethylene glycol linker of the general formula (III), wherein n= 1-14. A method of preparation of the aminooxylipids of general formula (I) characterized in that the acylation of-butoxycarbonyl-polymethylenediamine, or- butoxycarbonyl-polyethyleglycoldiamine in position C(2) symmetrically branched fatty acids of general formula (IV), in the presence of a condensation reagent, or from acid of general formula (I) derived acylchloride of general formula (V) produces-aminolipids of general formula (VI). These are converted to aminolipids of general formula (VII). By their condensation with-butoxycarbonyl-aminooxyacetic acid in the presence of condensation reagent,-aminooxylipids of general formula (VIII), which by debocylation afford aminooxylipids of general formula (I). Acylchlorides of general formula (V) are prepared by reaction of acid of general formula (IV) with oxalylchloride in the presence of catalytic amount of-dimethylformamide in an organic aprotic solvent.  The use of nontoxic aminooxylipids of the general formula I for construction of nontoxic self-assembly liposomal carriers of therapeutics presenting aminooxy groups and so-called &#34;post-liposomal&#34; modification of these carriers with biologically functional molecules using oxime ligation technique.
PURPOSE:To produce a modified protease exhibiting suppressed cutaneous sensitization and antigenicity and having excellent stability and high activity by reacting a protease with a polysaccharide having bonded triazine ring and produced by reacting a polysaccharide with cyanuryl chloride. CONSTITUTION:A polysaccharide bonded with triazine ring is synthesized by reacting a polysaccharide (preferably dextrin, pullulan, etc.) with cyanuryl chloride preferably at pH8-11. The amount of triazine ring in the bonded polysaccharide is preferably &gt;=3X10&lt;-4&gt;mol/l. The bonded polysaccharide is made to react with a protease originated preferably from microorganism (especially from genus Bacillus) at a weight ratio of &gt;=3/1. The obtained modified protease can be purified by ultrafiltration. gel-filtration, liquid chromatography, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a humanized antibody specifically reacting with a prostate-specific membrane antigen (PSMA) having a new V region amino acid sequence and its antibody fragment, a fusion antibody thereof and a diagnostic agent and a therapeutic agent for cancer using the humanized antibody, the antibody fragment or the fusion antibody.  &lt;P&gt;SOLUTION: The humanized chimeric antibody specifically reacts with the PSMA and comprises an H chain composed of an H-chain V-region containing a specific amino acid sequence and an H-chain C-region of a human antibody and an L chain composed of an L-chain V-region containing a specific amino acid sequence and an L-chain C-region of the human antibody. Furthermore, the antibody fragment thereof and the fusion antibody of the chimeric antibody to interleukin 2 or an anticancer agent adriamycin are provided. The diagnostic agent for cancer comprises the chimeric antibody or its antibody fragment. Furthermore, the therapeutic agent for the cancer comprises the antibody, the antibody fragment or the fusion antibody.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a fomentation sheet suitable for adhering to the skin surface of legs, shoulders, elbows, knees, loins, or the like, at which unpleasant feeling such as pain is felt.  &lt;P&gt;SOLUTION: This fomentation sheet is obtained by forming a fomentation sheet part 6, forming a center recessed part 8, inserting and attaching stone particles 9 having far infrared energy-radiating properties at low temperatures such as vermiculite and tourmaline into the center recessed part 8, and sticking a fixing adhesive sheet 12 thereto. The fomentation sheet part 6 is obtained by sandwiching a mixed powder layer 3 of a sap raw powder 1 obtained by drying and powdering sap such as pyroligneous acid or bamboo pyroligneous acid, and a stone powder 2 having the far infrared energy-radiating properties at low temperatures such as the vermiculite and the tourmaline between a cotton nonwoven fabric fragment 4 and a chemical nonwoven fabric fragment 5. The center recessed part 8 is formed over the surface part 7 of the chemical nonwoven fabric fragment 5 to the cotton nonwoven fabric fragment 6. The fixing adhesive sheet 12 has a projected adhesive part 11 projected from the perimeter part 10 of the chemical nonwoven fabric fragment 5 and capable of being stuck to the human skin, and is stuck to the surface part 7 of the chemical nonwoven fabric fragment so as to cover the stone particles 9.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide arachidonic acid oil and fat excellent in oxidation stability.  &lt;P&gt;SOLUTION: A composition containing an arachidonic acid is used for adding arachidonic acid or enhancing its content. The composition contains tocopherol and a rosemary extract together with arachidonic acid. The arachidonic acid may be an alcohol ester of arachidonic acid or triglyceride, phospholipid, or glycolipid arachidonic acid whose part or whole of the constituent fatty acid is arachidonic acid. It is desirable that the composition contain 1 wt.% or above of arachidonic acid. The rosemary extract is preferably an oil soluble extract, more preferably carnosic acid. The composition is added to food and drink-favorite food, bait and feed, health care-medicine, or cosmetics so as to add arachidonic acid or enhance its content.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an ozonized vegetable oil which is one of excellent methods for storing ozone in a form usable for applications of deodorization, bacterial removal and decoloration.  &lt;P&gt;SOLUTION: An ozone soap using the ozonized vegetable oil as a main raw material is provided. The ozonized vegetable oil can be used in the same manner as that of usual soap in applications where the soap can be used such as hand-washing with the soap or washing of clothes or during bathing of pets by providing the ozonized vegetable oil as the soap. As a result, e.g. fish smell clinging to hands during fish cooking can be removed simultaneously with the bacterial removal when the hand-washing is carried out with the ozone soap.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the Multi Drug Resistance-1 (MDR-1) gene.  &lt;P&gt;SOLUTION: There are provided the polynucleotide of a molecular variant MDR-1 gene which is associated with uptake of drugs by a target cell, and the vector comprising such the polynucleotide. Furthermore, the host cell comprising such the polynucleotide or vector and the use thereof for the production of variant MDR-1 proteins are also provided. In addition, the variant MDR-1 protein and the antibody specifically recognizing such the protein as well as the transgenic non-human animal comprising the polynucleotide or the vector are provided. The method for identifying and obtaining inhibitors for therapy of disorders related to the multifunction of the MDR-1 gene as well as the method for diagnosing the status of such disorders are provided. The method for diagnosing such the disease, and the pharmaceutical composition are also provided.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To produce the titled compd. having a vivid color and superior heat and light resistances by subjecting a fluorine-contg. miceous mineral swollen in a polar solvent to treatment with a specified soln. and heat treatment. CONSTITUTION:A swellable fluorine-contg. miceous mineral such as sodium- tetrasilicon mica is soaked in a polar solvent of 2-7pH such as water and swollen by stirring for several min - several hr. After the solvent is removed, the mica is treated with a soln. contg. at least one kind of cation (complex) having d electron or cation having pi electron. The cation is capable of absorbing energy in the visible region and may be [Co(NH3)6]&lt;3+&gt;. By the treatment, the cation is substd. for at least part of twelve coordinated interlayer cations in the mica. The mica is then heat treated at &lt;=1,200 deg.C.